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ABSTRACT 
The integrated stress response (ISR) is 
regulated by kinases that phosphorylate the α 
subunit of translation initiation factor 2 and 
phosphatases that dephosphorylate it. Genetic and 
biochemical observations indicate that the eIF2αP-
directed holophosphatase - a therapeutic target in 
diseases of protein misfolding - is comprised of a 
regulatory, PPP1R15, and a catalytic, Protein 
Phosphatase 1 (PP1) subunit. In mammals, there 
are two isoforms of the regulatory subunit, 
PPP1R15A and PPP1R15B, with overlapping 
roles in the essential function of eIF2αP 
dephosphorylation. However, conflicting reports 
have appeared regarding the requirement for an 
additional co-factor, G-actin, in enabling 
substrate-specific dephosphorylation by PPP1R15-
containing PP1 holoenzymes. An additional 
concern relates to the sensitivity of the 
holoenzyme to the [(o-
chlorobenzylidene)amino]guanidines Sephin1 or 
Guanabenz, putative small molecule proteostasis 
modulators. It has been suggested that the source 
and method of purification of the PP1 catalytic 
subunit and the presence or absence of an N-
terminal repeat-containing region in the 
PPP1R15A regulatory subunit might influence the 
requirement for G-actin and sensitivity of the 
holoenzyme to inhibitors. We find that eIF2αP-
dephosphorylation by PP1 was moderately 
stimulated by repeat-containing PPP1R15A in an 
unphysiological low ionic strength buffer, whereas 
stimulation imparted by the co-presence of 
PPP1R15A and G-actin was observed under a 
broad range of conditions: low and physiological 
ionic strength; whether PPP1R15A regulatory 
subunit had or lacked the N-terminal repeat-
containing region; and whether it was paired with 
native PP1 purified from rabbit muscle, or 
recombinant PP1 purified from bacteria. 
Furthermore, none of the PPP1R15A-containing 
holophosphatases tested was inhibited by Sephin1 
or Guanabenz. 
 
The integrated stress response (ISR) is a 
signal transduction pathway that couples diverse 
stressful conditions to the activation of a rectifying 
translational and transcriptional program that is 
implicated in biological processes ranging from 
memory formation to immunity and metabolism 
(reviewed in Ref. 1). The mammalian ISR and its 
yeast counterpart (the general control response) 
are initiated by the phosphorylation of the α 
subunit of translation initiation factor 2 (eIF2α) on 
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serine 51 (2,3) and its activity is terminated by 
eIF2αP dephosphorylation. 
Two related regulatory proteins, 
PPP1R15A/GADD34 and PPP1R15B/CReP, 
encoded in mammals by PPP1R15A and 
PPP1R15B, direct the unspecific Protein 
Phosphatase 1 (PP1) to promote eIF2αP 
dephosphorylation (4-7). PPP1R15A or 
PPP1R15B form a complex with PP1 via a 
conserved region of ~70 amino acids (PPP1R15A 
residues 555-624) located at their C-termini (5,8-
11) (Fig. 1A). This conserved C-terminal region of 
either PPP1R15 regulatory subunit is sufficient to 
promote eIF2αP dephosphorylation and to 
inactivate the ISR (4,5,10,11). Indeed, Herpes 
viruses have exploited this activity and encode a 
small protein homologous to the C-terminus of 
PPP1R15 to reverse eIF2α phosphorylation, 
undoing a defensive strategy of infected cells (12). 
Despite genetic evidence pointing to the 
sufficiency of the conserved C-terminal portion of 
PPP1R15 in reversing the eIF2αP-dependent ISR 
in vivo (4,5,10), complexes formed in vitro 
between PPP1R15 regulatory subunit fragments 
and PP1 have not been observed to accelerate 
eIF2αP dephosphorylation: dephosphorylation of 
eIF2αP is no faster by a complex of PPP1R15A-
PP1 (or PPP1R15B-PP1) than by PP1 alone, 
showing that when added as single components, 
PPP1R15A/B do not influence kcat or Km of PP1 
towards the substrate eIF2αP (10). However, 
addition of G-actin to the binary complex of 
PPP1R15 and PP1 selectively accelerates eIF2αP 
dephosphorylation. G-actin binds directly to the 
conserved C-terminus of PPP1R15, alongside PP1 
to form a ternary complex, whose affinity (Kd~10-8 
M) matches the EC50 of G-actin’s stimulatory 
effect (10,13). The in vivo relevance of G-actin to 
eIF2αP dephosphorylation is attested to by the 
finding that actin sequestration in fibres (as F-
actin) enfeebles eIF2αP dephosphorylation, 
implying a role for factors that affect the actin 
cytoskeleton in ISR regulation (14). 
The ability to dephosphorylate eIF2αP is 
an essential function in developing mammals (15). 
Nonetheless, inactivation of the PPP1R15A gene, 
which decelerates eIF2αP dephosphorylation and 
prolongs the ISR, is protective in certain cellular 
and animal models of diseases associated with 
enhanced unfolded protein stress (16-19). This has 
generated interest in targeting the PPP1R15A-
containing holophosphatase for inhibition by small 
molecules (reviewed in Ref. 20); an endeavour 
that requires detailed knowledge of the enzymatic 
mode of action. 
A recent report challenged the need for G-
actin as a co-factor in PPP1R15A-mediated eIF2αP 
dephosphorylation (21). Instead, it suggested that a 
binary complex assembled from PP1α and a 
fragment of PPP1R15A (PPP1R15A325-636), 
encompassing both the C-terminal PP1-binding 
region and the N-terminal repeat-containing 
extension, dephosphorylates eIF2αP faster than 
PP1 alone (21). Importantly, dephosphorylation of 
eIF2αP by this active binary complex was reported 
to be selectively inhibited in vitro by Guanabenz 
and Sephin1, two structurally-related small 
molecules that function in vivo as proteostasis 
modifiers (22,23). The new study contradicts 
previous observations that neither a PPP1R15A-
PP1 binary complex, nor a PPP1R15A-PP1-G-
actin ternary complex, were susceptible to 
inhibition by Guanabenz or Sephin1 (9,13).  
Here we address three important questions 
raised by these discrepant reports: Does the 
isotype of PP1 catalytic subunit or its source 
(recombinant versus native) influence the 
requirement for G-actin by the eIF2αP–directed 
holophosphatase? What role does the N-terminal 
repeat-containing region of PPP1R15A play in 
eIF2αP dephosphorylation by the 
holophosphatase? Do these factors influence the 
sensitivity of eIF2αP dephosphorylation to 




Both native PP1 and bacterially-expressed PP1α 
require the presence of G-actin to promote 
PPP1R15A-regulated eIF2αP dephosphorylation  
PP1 produced in E. coli may differ in its 
enzymatic activity from PP1 purified from animal 
tissues, both in its substrate specificity and in its 
sensitivity to regulatory subunits (reviewed in ref. 
24). To determine if the G-actin-dependence of 
PP1-PPP1R15A-mediated eIF2αP 
dephosphorylation is a peculiarity of the 
bacterially-expressed PP1γ isoform used 
previously (10,13), we purified the native catalytic 
subunit of PP1 from rabbit skeletal muscle (PP1N), 
following an established protocol (25), and 
compared the two PP1 preparations. Native PP1 
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(PP1N) is a mixture of PP1α, PP1β and PP1γ 
isoforms and gave rise to two prominent bands on 
SDS-PAGE (Fig. S1A, left panel). The mass 
spectra of tryptic peptides derived from the PP1N 
sample was analysed by Maxquant with iBAQ 
(intensity based absolute quant) to identify the 
major contaminating species (tropomyosin), and to 
estimate the relative contribution of PP1 and 
contaminants to the protein preparation. This 
enabled a comparison of the catalytic subunit 
content of PP1N preparation with the bacterially-
expressed PP1γ, which served as a reference. 
The N-terminal portion of PPP1R15A, 
which includes the membrane association region 
(26), compromises expression in bacteria and 
recovery of a functional protein (27). Therefore, 
we used a PPP1R15A325-636 fragment lacking this 
region, which is soluble when expressed in E. coli. 
Fig. 1B shows that addition of either 
PPP1R15A325-636-MBP (lanes 5-8), or G-actin 
alone (lanes 13 & 14) did not stimulate eIF2αP 
dephosphorylation by nanomolar concentrations of 
PP1N. However, addition of both G-actin and 
PPP1R15A325-636-MBP (lanes 9-12) stimulated 
dephosphorylation by 5-fold (Fig. 1B), similar to 
the increase observed with bacterially expressed 
PP1γ (Fig. S1B)(10).  
PP1 purified from rabbit muscle is a 
mixture of α, β and γ isoforms, whereas it has been 
reported that the PP1α isoform possesses in vivo 
selectivity for PPP1R15A (6). Therefore, we 
prepared bacterially-expressed PP1α by a method 
that promotes its native-like state (28). To control 
for effects the location of the tag might have on 
activity, we also generated an N-terminally MBP-
tagged PPP1R15A325-636 (MBP-PPP1R15A325-636, 
Fig. 1A, Table S1). The holophosphatase 
comprised of PP1α and MBP-PPP1R15A325-636 
also exhibited a stringent requirement for G-actin 
(Fig. 1C). 
A concentration-dependent stimulatory 
effect of PPP1R15A on eIF2αP dephosphorylation 
by the three component holoenzyme (PP1, 
PP1R15A and G-actin) was observed with 
constructs tagged at either their N- or C-termini 
and with either native or bacterially-expressed PP1 
(Fig. 2A and B). The difference in EC50 values 
obtained for PPP1R15A325-636-MPB with PP1N (58 
nM) or MBP-PPP1R15A325-636 with PP1α (6 nM) 
may reflect the effect of the position of the MBP-
tag, the contaminating tropomyosin (in PP1N), or 
both. Importantly, the data agreed with similar 
experiments in which PPP1R15A325-636 and 
bacterially-expressed PP1γ were used, EC50 of 10 
nM (13, Figure 8A therein).  
G-actin also exerted a saturable concentration-
dependent stimulatory effect on the activity of a 
three-component holophosphatase constituted with 
native PP1N (Fig. 2C). The EC50 for G-actin with 
PP1N (30 nM) was similar to that previously 
observed using bacterially-expressed PP1γ, EC50 
of 13 nM (13, figure 2C therein). Hence, despite 
variations in the estimated EC50 values for 
PPP1R15A or G-actin, the combinations of 
catalytic and regulatory subunits tested showed 
consistent PPP1R15A and G-actin concentration 
dependent enzymatic activity. These experiments, 
conducted in a buffer of physiological ionic 
strength, over a physiological protein 
concentration range (nanomolar catalytic subunit 
and micromolar substrate) and over a timescale 
aimed to minimize the effect of substrate depletion 
on enzyme kinetics, indicate that neither the 
source of PP1 nor the position of the tag in 
PPP1R15A are likely to account for the reported 
G-actin independent ability of PPP1R15A to 
stimulate eIF2αP dephosphorylation. 
  
Two-fold stimulation of eIF2αP 
dephosphorylation by repeat-containing 
PPP1R15A in an unphysiological low ionic 
strength buffer 
To explore the discrepant findings on the G-actin 
independent stimulatory activity of MBP-
PPP1R15A325-636 we sought to reproduce the 
experiments reported in reference 21 as closely as 
possible. We received from the Bertolotti 
laboratory their expression plasmid. The encoded 
protein, referred to here as MBP~PPP1R15A325-636 
(Fig. 1A) differs from the one used above (MBP-
PPP1R15A325-636) by the absence of three residues 
in the linker separating the MBP from PPP1R15A 
and 11 residues in the linker separating 
PPP1R15A from the C-terminal poly-histidine tag 
(see Table S1). The MBP~PPP1R15A325-636 fusion 
protein was produced in E. coli and purified as 
described (21) and dephosphorylation reactions 
were carried out in a salt-free, low ionic strength 
buffer, designed to mimic as close as possible the 
one used in that study (50 mM Tris at pH 7.4, 1.5 
mM EGTA, 2 mM MnCl2, with the notable 
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exception of 0.5 mM TCEP, added here to prevent 
inactivation of the catalytic subunit by oxidation).  
A 2-fold stimulation of eIF2αP 
dephosphorylation by MBP~PPP1R15A325-636 was 
apparent in reactions conducted at low salt 
concentration (15 mM), but lost at more 
physiological concentrations (100 mM), whilst the 
5-fold stimulatory effect of G-actin was observed 
at both low and physiological salt concentration 
(Fig. 3A). The stimulatory effect of 
MBP~PPP1R15A325-636 at low salt concentration 
was dependent on the N-terminal repeat-
containing region of PPP1R15A (Fig 3B), as 
reported (21), and was not observed with a non-
specific dephosphorylation substrate (Fig. S2A).  
Though modest (two-fold) and confined to 
non-physiological, low ionic strength conditions, 
this stimulatory effect was reproducibly observed 
also with the MBP-PPP1R15A325-636 and 
PPP1R15A325-636-MBP proteins used in Fig.1 and 
Fig.2 (Fig. S2B), negating a role for the linkers or 
the position of the tag in this activity. Notably, in 
both unphysiological-low ionic strength buffer (in 
which PPP1R15A alone has a stimulatory effect) 
and in physiological conditions, the presence of G-
actin dominates the kinetics of eIF2αP 
dephosphorylation. 
 
Lengthy incubation of the enzymatic reactions 
does not uncover PPP1R15A’s ability to promote 
G-actin-independent eIF2αP dephosphorylation 
at physiological salt concentrations 
Upon inhibition of the phosphorylating 
kinase, the eIF2αP signal decays with a T1/2 of <10 
minutes (with no change in the total eIF2α 
content) in both cultured mouse fibroblasts (Ref. 
14, figure 6 therein) and Chinese Hamster Ovary 
cells (Ref. 13, figure 10 therein). Despite the rapid 
in vivo kinetics of the dephosphorylation reaction, 
the experiments pointing to G-actin-independent 
eIF2αP dephosphorylation were conducted with 
long incubations of 16 hours at 30˚C (21). In the 
absence of other components, PP1α is markedly 
unstable at 30˚C, losing about half of its activity 
by 1 hour and all detectable activity by 3 hours 
(Fig. S3A and B). Thus, a stabilizing effect of a 
PP1 binding co-factor might have accounted for 
the apparent G-actin-independent stimulatory 
effect of MBP-PPP1R15A325-636 on PP1α-mediated 
eIF2αP dephosphorylation at physiological salt 
concentrations. However, over a range of PP1 
concentrations (0.2-200 nM), the presence of 
MBP-PPP1R15A325-636 failed to stimulate eIF2αP 
dephosphorylation, whether PP1N (Fig. 4A) or 
PP1α (Fig. 4B) were used as the catalytic subunit.  
 
Substrate recruitment by the repeat-containing 
PPP1R15A325-512 region plays a secondary role in 
the kinetics of eIF2αP dephosphorylation and its 
disruption is unlikely to account for sensitivity to 
Sephin1 
PPP1R15A interacts directly with eIF2α, 
both in cells (9) and in vitro (21). This interaction 
maps to the repeat-containing region of 
PPP1R15A, residues 325-512; N-terminal to 
PPP1R15A’s PP1-binding domain (Fig. 1A) and 
was proposed to play an important role in the 
catalytic cycle of PPP1R15A-containing 
holoenzymes (21). However, in the presence of G-
actin, PPP1R15A325-636-MBP and PPP1R15A533-
624-MBP (Fig. 1A, Table S1) stimulated eIF2αP 
dephosphorylation similarly, when paired either 
with PP1N (compare Fig. 2B and 5A here) or with 
PP1γ (compare Figure 8A and Figure 2B in Ref. 
13). These findings suggest that the conserved C-
terminal PPP1R15 fragment that binds PP1 and G-
actin simultaneously is sufficient to promote 
eIF2αP dephosphorylation and to dominate its 
kinetics in vitro and call in to question the 
importance of the N-terminal repeats in 
PPP1R15A to the fundamentals of the 
holoenzyme’s catalytic cycle. 
We considered that an important 
contributory role for substrate engagement by the 
PPP1R15A325-533 repeat-containing fragment to the 
catalytic cycle of the holophosphatase might have 
been masked by compensatory features that 
diverge between the different regulatory subunit 
constructs, fortuitously equalizing their activity. 
To address this possibility, we measured the 
ability of MBP-PPP1R15A325-512 containing the 
repeats but lacking the C-terminal PP1 binding 
region (Fig. 1A, Table S1) to compete with MBP-
PPP1R15A325-636-mediated (G-actin-dependent) 
eIF2αP dephosphorylation using PP1α as the 
catalytic subunit. Minimal inhibition of the 
dephosphorylation reaction was observed at 
competitor concentrations of up to 8 µM (Fig. 
5B), which is a >300-fold excess over the MBP-
PPP1R15A325-636 regulatory subunit (present in the 
reaction at 24 nM), and a concentration of 18-fold 
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above the reported Kd of the interaction between 
MBP-PPP1R15A325-512 and eIF2αP (21).  
These data suggest that substrate 
recruitment by the N-terminal extension of 
PPP1R15A plays a secondary role in the kinetics 
of the dephosphorylation reaction in vitro and that 
the reported role of Sephin1 and Guanabenz in 
disrupting that interaction is unlikely to make an 
important contribution to their pharmacological 
activity. Consistent with these conclusions we find 
that under physiological salt conditions in which 
eIF2αP dephosphorylation is dependent on the 
concentration of PP1α, MBP-PPP1R15A325-636 and 
G-actin, we were unable to observe an inhibitory 
effect of either Sephin1 (Fig. 6A and Fig. S4A, 
lanes 8-11) or Guanabenz (Fig. 6B and Fig. S4B, 
lanes 7-10) at a concentration of up to 100 µM 
which exceeds by a hundred-fold the concentration 
required for a proteostatic effect in cultured cells 
(1 µM)(23, figure 1F therein). Similarly, no effect 
of the compounds was observed on the PP1-
PPP1R15A holophosphatase activity in low salt 
conditions (Fig. S4A lanes 1-7 and Fig. S4B lanes 
1-6).  
Complete inhibition of PPP1R15A-
mediated eIF2αP –dephosphorylation by Sephin 1 
was reported in an assay conducted over 16 hours 
at 30˚C in a low ionic strength buffer (21). We 
wished to test if the reported Sephin1’s inhibition 
might be unmasked by this long incubation (in 
which the enzyme is undergoing inactivation, Fig. 
S3B). Using identical MBP~PPP1R15A325-636 and 
PP1α constructs, in an identical low ionic strength 
buffer and following overnight incubation at 30˚C, 
we observed a two-fold stimulation of eIF2αP–
dephosphorylation by MBP~PPP1R15A325-636 
(similar to that noted in shorter reactions Fig. 3). 
However, even in these conditions, designed to 
mimic as closely as possible those used in 
reference (21), the presence of 100 µM Sephin1 
was devoid of an inhibitory effect on substrate 
dephosphorylation (Fig. S4C) 
 
Discussion 
The new experiments presented here cover 
a range of conditions with realistic concentrations 
and time regimes. Incorporation of multiple time 
points and titrations of reaction components 
enabled a comparison of enzyme kinetics that 
accounts for the effect of substrate depletion. Our 
observations were made with four different 
PPP1R15A preparations, three different PP1 
preparations and both buffer conditions previously 
used in our lab and those used in reference (21), 
all of which consistently show the requirement for 
G-actin as an additional co-factor in enabling 
PPP1R15A to stimulate eIF2αP dephosphorylation 
in vitro. As such the results presented here are in 
keeping with previous observations that G-actin 
has an essential role in promoting eIF2αP 
dephosphorylation both in vitro and in vivo 
(10,13,14).  
The PP1 apo-enzyme is salt sensitive and 
inhibited by buffers of physiological ionic strength 
(29). By contrast, PP1-holoenzymes retain their 
regulated enzymatic activity at physiological ionic 
strength (30). These considerations call into 
question the significance of the two-fold 
stimulation of eIF2αP dephosphorylation by 
PPP1R15A325-636 observed in buffer of low ionic 
strength. Our experiments also cast doubt on the 
importance of the physical interaction between the 
repeat-containing region of PPP1R15A (residues 
325-512) and eIF2αP in substrate-specific 
dephosphorylation reaction carried out in 
physiological ionic strength. PPP1R15 regulatory 
subunits are found throughout the animal 
kingdom, yet only their C-terminal ~70 residues 
are conserved (11). This C-terminal fragment 
contains all the information needed to promote 
eIF2αP dephosphorylation, as exemplified by its 
selective hijacking by Herpes viruses (12) and by 
experimentally targeted expression in cells (10, 
figure 1C therein). In complex with G-actin, the 
conserved C-terminal fragment of the PPP1R15s is 
also able to direct PP1 to selectively 
dephosphorylate eIF2αP in vitro (Fig. 2 and 5A 
here and (10,13).  
The prominent stimulatory role of G-actin 
on eIF2αP dephosphorylation, observed both in 
vivo and in vitro, should not obscure the 
possibility that binary complex formation with 
PPP1R15 might also favour eIF2αP 
dephosphorylation independently of G-actin 
joining the complex. Regulatory subunit binding 
restricts access to PP1 (24,31), favouring the 
phosphorylation of one class of substrates over 
another. Mere exclusion of some substrates from 
access to the catalytic subunit might accelerate 
eIF2αP dephosphorylation when levels of 
PPP1R15A levels are sufficiently elevated in cells 
– even though in vitro (and in the absence of 
Reconstitution of a PPP1R15A-containing holophosphatase 
 6 
competing substrates) the PPP1R15A-PP1 binary 
complex is not a faster eIF2αP phosphatase than 
PP1 alone (provided the experiments are 
conducted at physiological salt concentrations). As 
neither Sephin1 nor Guanabenz affect the stability 
of the PPP1R15A-PP1 complex (13), it is unlikely 
that they achieve any measure of inhibition by 
weakening PPP1R15A’s ability to compete with 
other regulatory subunits for limiting amounts of 
catalytic subunit. These considerations lead us to 
propose a dual role for PPP1R15A in cells: 
Diverting limiting amounts of PP1 away from 
other substrates towards eIF2αP and, in 
conjunction with G-actin as an essential co-
activator, stimulating the intrinsic rate of 
dephosphorylation by the holoenzyme thus 
formed. Actin, too, has a dual role in stimulating 
eIF2αP dephosphorylation: by stabilizing the 
PPP1R15-PP1 complex (14) G-actin favours the 
exclusion of other regulatory subunits, whilst 
stimulating enzyme kinetics selectively towards 
eIF2αP (Fig. 7).  
Here we present no argument against an 
important function for the divergent N-terminal 
extensions of PPP1R15 regulatory subunits. This 
role may play out in terms of subcellular 
localization (26) or protein stability (32) and might 
be influenced by a physical interaction with the 
substrate (9,21). However, our findings argue that 
the physical interaction noted previously between 
PPP1R15A residues 325-512 and eIF2αP (21) is 
unlikely to play an important role in formation of 
the enzyme-substrate complex required for 
catalysis under physiological conditions and hence 
its disruption by Guanabenz or Sephin1 is unlikely 
to underscore an inhibitory effect on eIF2αP 
dephosphorylation.  
Most importantly perhaps, the findings 
presented here argue that the inability of previous 
efforts to uncover a role for Guanabenz or Sephin1 
in inhibiting eIF2αP dephosphorylation in vitro 
(9,13) was unlikely to have arisen from choice of 
catalytic subunit, from features of the PPP1R15A 
regulatory subunit or the buffer conditions used. 
Rather, the findings reported here, made in vitro, 
reinforce observations that Sephin1 and 
Guanabenz have no measurable effect on the rate 
of eIF2αP dephosphorylation in cells (13). The 
recent description of PPP1R15A/GADD34-
independent cellular effects of Guanabenz (33) 
and our observations that Sephin1-induced 
changes in gene expression were noted both in 
cells lacking PPP1R15A and in cells with non-
phosphorylatable eIF2α (13), suggest the need to 
reconsider the role of these two compounds as 
eIF2αP dephosphorylation inhibitors. 
 
Experimental procedures 
Protein expression and purification 
The plasmids used to express protein in E. 
coli and the sequence of the encoded proteins are 
listed in Tables S1 and S2. 
PPP1R15A325-636-MBP and PPP1R15A533-
624-MBP were produced as described (13). Briefly, 
proteins were expressed in E. Coli BL21 (New 
England Biolabs, Cat. No.C3013) as N-terminally-
tagged glutathione S-transferase fusion proteins 
and were purified by tandem affinity 
chromatography, first bound to a glutathione 
sepharose 4B resin, eluted with glutathione, 
followed by an overnight cleavage with Tobacco 
Etch Virus (TEV) protease (to remove the GST 
tag), binding to amylose beads and elution in 
maltose-containing buffer.  
MBP-PPP1R15A325-636 and MBP-
PPP1R15A325-512 were constructed in the C-
terminally hexahistidine tag-containing pMAL-
c5x-His plasmid (New England Biolabs, Cat. No. 
N8114). Transformed E. Coli BL21 (New England 
Biolabs, Cat. No. C3013) were selected on LB 
agar plates supplemented with 100 µg/ml 
ampicillin. A single colony was picked to grow 
overnight in 5 mL starter culture that served to 
inoculate 2 L of LB media (all supplemented with 
100 µg/mL ampicillin), which was kept at 37°C. 
At OD600=0.6-0.8 protein expression was induced 
using 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 18°C for 20 
hours. Bacteria were pelleted and resuspended in 
ice-cold His6 Lysis Buffer containing 50 mM Tris 
pH 7.4, 500 mM NaCl, 1 mM MgCl2, 1 mM tris 
(2-carboxyethyl)phosphine (TCEP), 100 µM 
phenylmethylsulfonyl fluoride (PMSF), 20 
mTIU/ml aprotinin, 2 µM leupeptin, and 2 µg/ml 
pepstatin 20 mM imidazole and 10% glycerol.  
Bacterial suspensions were lysed using an Emulsi-
Flex-C3 homogenizer (Avestin, Inc, Ottawa, 
Ontario) and clarified in a JA-25.50 rotor 
(Beckman Coulter) at 33,000 x g for 30 min at 
4°C. Pre-equilibrated Ni-NTA beads (Qiagen, Cat. 
No. 30230,) were incubated with the samples for 2 
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hours at 4°C. Proteins were eluted in 2 mL of 
imidazole elution buffer (50 mM Tris, pH 8, 100 
mM NaCl, 500 mM imidazole, 10% glycerol) and 
incubated with amylose beads (New England 
Biolabs, Cat No. E8021S) pre-equilibrated with 
lysis buffer (His6 lysis buffer without imidazole) 
for 2 hours at 4°C. The amylose beads were batch-
washed using 25 bed volumes of lysis buffer and 
proteins were eluted with amylose elution buffer 
(lysis buffer + 10 mM maltose). MBP-R15A325-512 
purification required an additional buffer exchange 
step (into lysis buffer) using Centripure P1 de-
salting columns (EMP Biotech, Cat. No. CP-0110) 
to eliminate maltose (that appeared to interfere 
with the dephosphorylation reactions when present 
at high concentrations).  
MBP~PPP1R15A325-636 (a gift of the 
Bertolotti lab) was expressed and purified as 
described (21), with minor modifications: The 
IPTG-induced culture was maintained for 16 hours 
at 18˚C and 0.5 mM TCEP was included in all 
buffers, throughout the purification procedure and 
in the final dialysis buffer (50 mM Tris at pH 7.4, 
200 mM NaCl, 0.5 mM TCEP). 
eIF2αP: The N-terminal fragment of 
human eIF2α (1-185, with three solubilizing 
mutations) was purified from bacteria and 
phosphorylated in vitro using the kinase domain of 
PERK, as described (10). 
G-actin was purified from rabbit muscle 
according to ref. (34) as modified in ref. (10). 
PP1γ (7-300) was purified according to 
ref. (13).  
PP1α (7-330) was purified from BL21 E. 
coli according to ref. (28,35) 
PP1N was purified from rabbit muscle 
according to ref. (25)  
In vitro dephosphorylation reactions 
Unless otherwise stated, 
dephosphorylation reactions were performed at a 
final volume of 20 µL by assembling 5 µL of 4× 
solution of each component: PP1, PPP1R15A, G-
actin and eIF2αP (or their respective buffers). A 
10X assay buffer (500 mM Tris pH 7.4, 1 M NaCl, 
1 mM EDTA, 0.1% Triton X-100, 10 mM MgCl2) 
was diluted 1:10, supplemented with 1 mM DTT 
and used to create working solutions of PP1, 
PPP1R15A and eIF2αP at the desired 
concentrations. G-actin working solutions were 
created using G-buffer (2 mM Tris-HCl at pH 8, 
0.2 mM ATP, 0.5 mM DTT and 0.1 mM CaCl2). 
Holoenzyme components (PP1, PPP1R15A and G-
actin) were combined first and substrate (eIF2αP) 
was added last to initiate the reactions, which were 
conducted under shaking at 500 rpm and at 30˚C 
for the specified time. The final buffer 
composition was 36 mM Tris pH 7.4, 76 mM 
NaCl, 74 µM EDTA, 0.007 % Triton X-100, 0.7 
mM MgCl2, 25 µM CaCl2, 0.05 mM ATP and 0.8 
mM DTT, 0.5 µM Latrunculin B, 0.4 - 3 µM 
MnCl2, 0.5% Glycerol and 50 µM TCEP, in 
experiments performed in Fig. 1, Fig. 2, Fig. 4, 
Fig. 5, Fig. 6, Fig. S1, Fig. S3 and Fig. S4A (lanes 
8-11) and Fig. S4B (lanes 7-10).  
Dephosphorylation reactions designed to 
reproduce the observations of ref. (21) were 
performed in the assay buffer described therein 
(50 mM Tris-HCl pH 7.4, 1.5 mM EGTA pH 8.0, 
2 mM MnCl2), with the modification that 0.5 mM 
TCEP was added to disfavor oxidative inactivation 
of the enzyme. The NaCl content of the final 
reaction was constrained by the contribution of the 
protein solutions added to each reaction. To 
maintain parity between reactions performed with 
and without PPP1R15A, an equal volume of the 
PPP1R15A buffer was added to reactions lacking 
the protein. The final salt concentration in the 
various reactions is noted in the figure legends.  
 The stability test of PP1α (Fig. S3) was 
performed by preparing a fresh 240 nM solution of 
PP1α in the assay buffer described above. Separate 
aliquots were pre-incubated either at 30˚C or on 
ice for the specified times (30 minutes to 7 hours, 
see schema in Fig. S3A). At termination of the 
pre-incubation, 5 µL of these pre-incubated 
solutions were added into 20 µL 
dephosphorylation reactions as described above.  
Dephosphorylation reactions to test the 
activity of Sephin1 or Guanabenz (Fig. 6 and Fig. 
S4) included a 15 minutes pre-incubation of the 
enzymatic components at room temperature 
(before addition of substrate) with either Sephin1 
(Enamine, Cat. No. EN300-195090), Guanabenz 
(Sigma-Aldrich, Cat. No. D6270), Tautomycin 
(Calbiochem, Cat. No. 5805551) or an equal 
volume of DMSO (vehicle).  
Reactions were terminated by addition of 
10 µL of 3× Laemmli buffer supplemented with 
100 mM DTT and heating the samples for 5 
minutes at 70˚C. A third (10 µL) of the final 
volume was resolved in 12.5% PhosTag SDS gels 
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(Wako, Cat. No. NARD AAL-107) at 200 V for 1 
hour. Gels were stained with Coomassie Instant 
Blue and imaged on an Odyssey imager (LI-COR, 
Lincoln, NE). 
ImageJ was used to quantify eIF2αP 
dephosphorylation as reflected by the intensity of 
the fluorescence arising from the Coomassie stain 
of the eIF2αP and eIF2α0 bands resolved by the 
PhosTag SDS-PAGE gels and captured as a TIF 
file on Odyssey imager. GraphPad Prism v8 was 
used to fit plot and perform statistical analysis. 
Table S3 lists the number of times each 
experiment was performed. 
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Table S1. PPP1R15A protein variants used in this study






































Table S2. Plasmids used in this study
Lab number Lab name Description Abbreviation Reference
UK105 eIF2a-NM_pET30a His6-tagged human eIF2a 1-185 pET-30a(+)" eIF2a PMID 15341733
UK168 PerkKD-pGEX4T-1 Bacterial expression plasmid for mouse PERK kinase domain PERK PMID 9930704
UK622 PGV_PP1G_1-323_V1 Bacterial expression plasmid for full-length PP1 phosphatase catalytic domain PP1G PMID 25774600
UK1920* huPPP1R15A_533_624_malE_pGEX_TEV_AviTag (MP1) Bacterial expression plasmid for N-tern AviTagged human GADD34 533-624 R15A533-624-MBP PMID: 28447936
UK1921* huPPP1R15A_325_636_malE_pGEX_TEV_AviTag (MP4 Bacterial expression plasmid for N-tern AviTagged human GADD34 325-624 R15A325-636-MBP PMID: 28447936
UK2258* huPPP1R15A_325-636_pMAL-c5X-H6 (AB)** Bacterial expression plasmid for MBP_1R15A(325-636)-H6 MBP~R15A325-636 PMID: 28759048
UK2260* MBP_huPPP1R15A_325-636_H6_pMAL-c5X-His Bacterial expression plasmid for  MBP_R15A(325-636)-H6 MBP-R15A325-636 This study
UK2261* MBP_huPPP1R15A_325-512_H6_pMAL-c5X-His Bacterial expression plasmid for MBP_R15A(325-512)-H6 (N-term) MBP-R15A325-512 This study
UK2264 PP1A_7-330_RP1B (MPC) Bacterial expression plasmid for H6-TEV-rabbit PP1A 7-330 Peti lab (Addgene Plasmid# 26566) PP1a PMID: 18992256 
*The sequence of the proteins encoded by these plasmids is available as Table S1
**A gift from Anne Bertolotti's laboratory
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Figure 1. G-actin stimulates PPP1R15A-dependent eIF2αP dephosphorylation by either PP1N or PP1α 
A, Cartoon representation of human PPP1R15A protein (1-674) and the different constructs used in this study (sequence provided
in Table S1). Key residues used for truncated versions of the proteins in this study are annotated. The ER localization domain and 
the proline, glutamate, serine and threonine-rich (PEST) repeats are highlighted as are the PP1 and G-actin binding sites in the 
conserved C-terminal region. MBP solubility tag is also represented in the cartoons of the constructs. B, Upper panel: 
Coomassie-stained PhosTag-SDS-PAGE containing resolved samples of dephosphorylation reactions (30 minutes at 
30˚C) in which 2 μM eIF2αP was dephosphorylated by PP1N purified from rabbit skeletal muscle in the presence or absence of 
PPP1R15A325-636-MBP (50 nM) and/or G-actin (400 nM).The position of the various protein species is indicated. eIF2αP and 
eIF2α0 refer to the phosphorylated and non-phosphorylated form of the bacterially-expressed N-terminal domain (residues 1-185)
 of eIF2α, respectively. Note that both G-actin and PP1N preparation gave rise to two bands: a major full-length species and minor 
degradation product, in the case of G-actin, and a PP1and tropomyosin band in the case of PP1N (see also Fig. S1). Shown is a 
representative experiment of two independent repetitions performed. Middle panel: Plot of the rate of eIF2αP dephosphorylation 
as a function of the concentration of PP1N from lanes 1 to 12 of experiment above. Bottom panel: Plot of the velocity of each enzyme 
relative to the mean of velocity of PP1 alone calculated from all the informative reactions in the two repeats of this experiment. 
Statistical significance derived from Mann-Whitney test (ns, non significant, p > 0.05; ***, p≤ 0.001). C, as in “B” but using 
bacterially-expressed PP1α as the catalytic subunit (96, 48, 24 or 12 nM), MBP-PPP1R15A325-636 (50 nM) and G-actin (400 nM). 
The assays were performed during 20 minutes at 30˚C. Shown is a representative experiment of two independent repetitions 
performed.  
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Figure 2. The source of catalytic subunit does not affect the kinetics of PPP1R15A and G-actin-mediated 
stimulation of eIF2αP dephosphorylation. A, Upper panel: Coomassie-stained PhosTag-SDS-PAGE of 
dephosphorylation reactions (30 minutes at 30˚C), in which 2 μM eIF2αP was dephosphorylated by PP1N (20 nM)
in presence of G-actin (400 nM) and increasing concentrations of PPP1R15A325-636-MBP (0-100 nM). Shown is a 
representative experiment of three independent experiments performed. Lower panel: Plot of the rate of 
dephosphorylation of eIF2αP as a function of PPP1R15A325-636-MBP concentration, from the three experiments 
performed. The EC
50
 was calculated using the ”[Agonist] vs. response - variable slope (four parameters)” function in GraphPad 
Prism v7. The grey lines represent the 95% confidence interval of the fitting. Shown are values obtained for EC
50
 
and information of goodness of the fit (r2). B, as in “A” but using bacterially-expressed PP1α (24 nM) and increasing concentrations 
of MBP-PPP1R15A325-636 (0-100 nM) in reactions performed over 20 minutes at 30˚C. Shown is a representative 
experiment of three independent experiments performed. C. As in “A” but with fixed concentrations of PP1N (20 nM)
and PPP1R15A325-636-MBP (50 nM) and varying the concentrations of G-actin (1-2000 nM). Shown is a representative
experiment of three independent experiments performed.
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Figure 3. PPP1R15A325-636 accelerates eIF2αP dephosphorylation by PP1α  in a low ionic strength buffer.
 A, Upper panel: Coomassie-stained PhosTag-SDS-PAGE containing resolved samples of dephosphorylation reactions (30 minutes at 
30˚C) in which 2 μM eIF2αP was dephosphorylated by PP1α (25 or 100 nM) in the presence or absence of MBP~PPP1R15A325-636 (1 μM) 
with or without G-actin (400 nM) in low (15 mM NaCl) or physiological (100 mM NaCl) ionic strength buffer. Shown is a 
representative experiment of three independent repetitions performed. Lower panel: Plot of the percentage of eIF2αP dephosphorylation 
at the different conditions from the experiment above and the two other repeats performed. Statistical significance derived from paired 
two tailed t-test, (ns, non significant, p > 0.05; *, p ≤ 0.05; **, p≤ 0.01). B, as in “A” but using PPP1R15A533-624-MBP (200 nM). 
Shown is a representative experiment of three independent repetitions performed.  
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Figure 4. At physiological ionic strength and in the absence of G-actin, PPP1R15A is unable to stimulate dephosphorylation
 of eIF2αP (despite an extended incubation of 16h). A, Upper panel: Coomassie-stained PhosTag-SDS-PAGE containing 
dephosphorylation reactions (16 hours at 30˚C) in which 2 μM eIF2αP was dephosphorylated by the indicated concentration of 
PP1N in the presence or absence of PPP1R15A325-636-MBP (50 nM). Quantification of percentage of dephosphorylation (%dP) 
is shown below the image. Shown is a representative experiment of two independent repetitions performed.Lower panel: Plot of 
the rate of dephosphorylation of eIF2αP as a function of PP1N concentration. Data was obtained by quantification of bands of image
 shown above and the other repeat performed. B, as in “A” but using PP1α as the source of catalytic subunit and 
MBP-PPP1R15A325-636 (50 nM) as the regulatory subunit. Shown is a representative experiment of two independent repetitions 
performed.
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Figure 5. The C-terminal portion of PPP1R15A is sufficient to promote eIF2αP dephosphorylation. A, Upper panel:
Coomassie-stained PhosTag-SDS-PAGE containing resolved samples from dephosphorylation reactions (30 minutes at 
30˚C) in which 2 μM eIF2αP was dephosphorylated by PP1N (20 nM) in the presence of G-actin (400 nM) and increasing
concentrations of PPP1R15A533-624-MBP (0-100 nM). Shown is a representative experiment of three independent repetitions
performed. Lower panel: Plot of the rate of dephosphorylation of eIF2αP as a function of PPP1R15A533-624-MBP concentration,
from the three experiments performed. The EC
50
 was calculated using the ”[Agonist] vs. response - variable slope (four parameters)”
 function in GraphPad Prism v7. The grey lines represent the 95% confidence interval of the fitting. Shown are values obtained 
for EC
50
 and information of goodness of the fit (r2). B. as in “A” but using PP1α (24 nM) in presence of MBP-PPP1R15A325-636 (24 nM), 
G-actin (400 nM) and increasing concentrations of MBP-PPP1R15A325-512 as a competitor (0-8 μM). The assays were performed during 
20 minutes at 30˚C. Lane 8, loaded with only MBP-PPP1R15A325-512 shows the absence of a species co-migrating with eIF2α0 
(which might otherwise obscure an inhibitory effect on dephosphorylation). Lanes 9 and 10 control for the dependence of 
enzymatic activity on PPP1R15A and G-actin in this experiment. Quantification of percentage of dephosphorylation (%dP) is
shown below the image. Shown is a representative experiment of two independent repetitions performed. 
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Figure 6. Neither Sephin1 nor GBZ interfere with eIF2αP dephosphorylation A, Coomassie-stained PhosTag-SDS-PAGE
containing resolved samples from dephosphorylation reactions (20 minutes, 30˚C) in which 2 μM eIF2αP was 
dephosphorylated by PP1α (24 nM) in presence or absence of MBP-PPP1R15A325-636 (60 nM) and/or G-actin (400 nM). 
The components were pre-incubated as specified with either Sephin1 (100 μM), Tautomycin (80 nM) or DMSO (vehicle)
for 15 minutes at room temperature before being added to the reaction. The bottom panel shows a long exposure of the 
relevant section of the image above corresponding to the phosphorylated and non-phosphorylated forms of eIF2α. 
Quantification of percentage of dephosphorylation (%dP) is shown below the image. Shown is a representative experiment
of three independent experiments performed. B, as in “A” but with Guanabenz (GBZ). Shown is a representative experiment















































































Figure 7. Model depicting PPP1R15A’s role in regulating eIF2αP dephosphorylation. A, In absence of PPP1R15A the cellular
pool of catalytic subunit (PP1) is preferentially bound by a variety of regulatory subunits (R1, R2, R3) which direct its phosphatase
activity towards their specific substrates (S1, S2, S3), excluding eIF2α
P. In the substrate conversion section, see the preferential 
dephosphorylation of substrates S1, S2 and S3 (solid arrow) compared to eIF2α (dotted arrow). B, Rising levels of PPP1R15A recruit 
PP1 away from other regulatory subunits, redirecting its phosphatase activity towards eIF2αP by excluding other substrates. In the 
substrate conversion section, observe the inverted preferential dephosphorylation of substrates compared to “A”. C, When present, 
G-actin joins the PPP1R15A-PP1 holophosphatase, increasing its intrinsic eIF2αP-directed catalytic activity. In the 
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Supporting Figure 1. Analysis of the purity of the different sources of PP1. A, Coomassie-stained SDS-PAGE
in which different amounts of PP1 sample have been resolved. The PP1N preparation gave rise to two bands: 
a PP1 and tropomyosin band. The PP1γ preparation contained some free Glutathione S Transferase (GST) and 
GST-PP1 fusion protein from the purification steps, as well as other minor contaminants (*). The PP1 concentration
in the different preparations is shown below the panels, calculated using PP1γ as a reference. B, Coomassie-stained
PhosTag-SDS-PAGE containing resolved samples from dephosphorylation reactions (as in Fig. 1A and B) in which 
2 μM eIF2αP was dephosphorylated using bacterially-expressed PP1γ (24 nM) in presence or absence of 
MBP-PPP1R15A325-636 (50 nM), MBP-PPP1R15A325-512 (50 nM) and/or G-actin (400 nM) for 20 minutes at 30˚C. 
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 Supporting Figure 2. PPP1R15A325-636 selectively accelerates eIF2αP dephosphorylation by PP1α in a low ionic strength buffer.
 A, Upper panel: Coomassie-stained PhosTag-SDS-PAGE containing resolved samples of dephosphorylation reactions (30 minutes at 
30˚C) in which 2 μM GSTP (a non specific substrate) was dephosphorylated by PP1α (25nM) in the presence or absence of 
MBP~PPP1R15A325-636 (1 μM) with or without G-actin (400 nM) in low  (15 mM NaCl) ionic strength buffer. Shown is a representative 
experiment of three independent repetitions performed. Lower panel: Plot of the percentage of eIF2αP dephosphorylation at the different 
conditions from the experiment above and the two other repeats performed. Statistical significance derived from paired two tailed 
t-test,(ns, non significant, p > 0.05). B, as in “A” but using PPP1R15A325-636-MBP (200 nM), MBP~PPP1R15A325-636 (200 nM) or 





































































Supporting Figure 3. PP1α is an unstable enzyme. A, Schema of the experiment. Samples of PP1α (at 240 nM)
were pre-incubated for the indicated period of time, either on ice or at 30˚C, before being diluted into a eIF2αP
dephosphorylation reaction. B, Upper panel: Coomassie-stained PhosTag-SDS-PAGE containing samples from
dephosphorylation reactions (20 minutes at 30˚C) in which 2 μM eIF2αP was dephosphorylated by the pre-incubated
PP1α (60 nM) in presence of MBP-PPP1R15A325-636 (60 nM) and G-actin (400 nM). Lower panel. Plot of the rate of
dephosphorylation of eIF2αP as a function of pre-incubation time of PP1α catalytic subunit. Data was obtained by 
quantification of bands of image shown above. 
Supporting Figure 4. Neither Sephin1 nor GBZ interfere with eIF2αP dephosphorylation. A, Upper panel: 
Coomassie-stained PhosTag-SDS-PAGE containing resolved samples from dephosphorylation reactions (30 minutes, 
30˚C) in which 2 μM eIF2αP were dephosphorylated by PP1α (25 nM) in presence of MBP~PPP1R15A325-636 (1 μM) 
in either low ionic strength buffer (15 mM NaCl, without G-actin, lanes 2-7), or in physiological ionic strength buffer
(100 mM, with 400 nM G-actin, lanes 8-11) in presence of Sephin1 (or DMSO carrier). Shown is a representative of 
two independent experiments performed. Lower panel: Plot of percentage inhibition observed in all samples of the 
experiment shown above and its repeat (calculated separately in each experiment relative to the no-compound 
condition, 0 μM). B, as in “A” but with Guanabenz (GBZ). Percentage of dephosphorylation shown below the image.
C, Upper panel: as in “A” but following extended  incubation time of dephosphorylation reactions (18 hour, 30˚C) 
performed in presence of the indicated concentrations of PP1α in the absence or presence of MBP~PPP1R15A325-636 
(1 μM) and Sephin1 (100 μM). Shown is a representative of two independent experiments performed. Lower panel: 
Plot of the percentage of eIF2αP dephosphorylation  from the experiment above and the other repeat performed
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